Professor Işıl Somalı
Kurzbiografie
Prof. Dr. Işıl Somalı ist im Bereich der Medizinischen Onkologie tätig. Die Ausbildung umfasst ein grundständiges Studium an der Medizinischen Fakultät der Ege-Universität, die Facharztausbildung für Innere Medizin und die Schwerpunktweiterbildung in Medizinischer Onkologie an der Medizinischen Fakultät der Dokuz-Eylül-Universität. Zu den beruflichen Stationen zählen das Atatürk Ausbildungs- und Forschungskrankenhaus (2003-2011) und das Onkologische Institut der Dokuz-Eylül-Universität (2011-2021).
Ausbildung
Grundständiges Studium: Medizinische Fakultät der Ege-Universität, Juni 1994
Facharztausbildung: Medizinische Fakultät der Dokuz-Eylül-Universität, Abteilung für Innere Medizin, April 1999
Ernennung zum außerordentlichen Professor: Innere Medizin (Titel: April 2010, Stelle: Oktober 2011)
Professur: Onkologisches Institut der Dokuz-Eylül-Universität, Juni 2015
Berufserfahrung
- Schwerpunktweiterbildung: Medizinische Fakultät der Dokuz-Eylül-Universität, Abteilung für Innere Medizin, Fachbereich Medizinische Onkologie (Januar 2002)
- Medizinische Onkologie, İzmir Atatürk Ausbildungs- und Forschungskrankenhaus (2003–2011)
- Onkologisches Institut der Dokuz-Eylül-Universität (2011–2021)
- İzmir Özel Egepol Krankenhaus (2022–2025)
- İzmir Tınaztepe Universität, Özel Galen Krankenhaus (2026–)
Wissenschaftliche Arbeiten und Veröffentlichungen
Betreute Abschlussarbeiten
Abgeschlossene Facharztarbeiten
- Arbeitstitel: Verwendung des Neutrophilen-/Lymphozyten-Verhältnisses (NLR), des Thrombozyten-/Lymphozyten-Verhältnisses (PLR) und des mittleren Thrombozytenvolumens (MPV) als Biomarker für die Früherkennung und Prognose von Patienten mit kolorektalem Karzinom unter adjuvanter Behandlung. Studierende/r: Dr. Abdullah Murat BUYRUK (Mart 2012 - Mart 2016)
- Arbeitstitel: Klinisch-pathologische Untersuchung von Patienten mit malignem Melanom. Studierende/r: Dr. Hüsrev Önder AYDIN (Şubat 2009 - Şubat 2013)
- Arbeitstitel: Behandlung und Überlebensergebnisse bei unseren Patienten mit der Diagnose eines metastasierten malignen Melanoms. Studierende/r: Dr. Hüsrev Önder AYDIN (Şubat 2009 - Şubat 2013)
Laufende Facharztarbeiten
- Arbeitstitel: Einfluss der Eosinophilen-/Lymphozyten-Verhältnisse vor und nach neoadjuvanter Chemotherapie auf das Ansprechen auf die Chemotherapie und die Prognose bei Patienten mit lokal fortgeschrittenem Brustkrebs. Studierende/r: Dr. Öykü ÜNSAL (Eylül 2019 - läuft)
- Arbeitstitel: Diagnostische und prognostische Bedeutung von RDW und anderen Entzündungsparametern bei Patienten mit Magenkrebs. Studierende/r: Dr. Tolga GÖZMEN (Eylül 2019 - läuft)
- Arbeitstitel: Prognostische Bedeutung von MPV, RDW und Eosinophilenwerten bei der Beurteilung des Therapieansprechens und der Prognose bei Patienten mit Rektumkarzinom unter neoadjuvanter Behandlung. Studierende/r: Dr. Berna DEMİR YÜKSEL (Eylül 2019 - läuft)
Zeitschriftenpublikationen
Nach der Ernennung zum außerordentlichen Professor veröffentlichte Artikel
- Ayhan Z, Uslu S, İpek ŞC, Ünal S, Önen F, Somalı I, Saatci AO, “Nivolumab-Related Unilateral Panuveitis in a Patient with Metastatic Malignant Melanoma”, Retina-Vitreus, 2020; 29: 340-344.
- Semiz HS, Kazaz NS, Demir N, Güç ZG, Yavuzşen T, Ellidokuz H, Öztop İ, Somalı I, “Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma”, International Journal of Hematology and Oncology, 2020, Vol 30, Num 4, 103-109.
- Umut Varol, Yuksel Küçükzeybek, Ahmet Alacacıoğlu, Somalı I, Altun ZS, Aktaş S, Tarhan MO, “BRCA genes: BRCA 1 and BRCA 2”, J BUON, 23/4/862-866, 2018.
- Yıldırım S, Kazaz SN, Semiz HS, Yavuzşen T, Somalı I, Ellidokuz H, Öztop İ, “An Evaluation of the Information Sources of Cancer Patients' Relatives. A Prospective Survey.”, J Cancer Educ., 2018 Jul 13.
- Esin Oktay, Utku oflazoğlu, Yelda Varol, Özgür Tanrıverdi, Hayri Üstün Arda, Lütfiye Demir, Özge Keskin, Tural Ahmadli, Somalı I, Öztop İ, Nejla Mermut, Nezih Meydan, “The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma”, Journal of Cancer Research and Therapatics, 14/5 1201-1208, 2018.
- A. Murat BUYRUK, Seher Nazlı KAZAZ, İlhan ÖZTOP, Hüseyin S. SEMİZ, Utku OFLAZOĞLU, Işıl SOMALI, “The Use of Neutrophil/Lymphocyte Ratio (NIr), Platelet/Lymphocyte Ratio (Plr), and Mean Platelet Volume (Mpv) As Inflammatory Biomarkers in the Prognosis of Patients with Early-Stage Colorectal Adenocarcinoma”, International Journal of Hematology and Oncology, 4/27/220-228, 2017.
- Demir L, Can A, Öztop R, Dirican A, Bayol V, Küçükzeybek Y, Erten Ç, Somalı I, Akyol M, Tarhan MO, “Malignant epithelioid hemangioendothelioma progressing after chemotherapy and Interferon treatment: A case presentation and a brief review of the literature”, Journal of Cancer Research and Therapeutics, 2015.
- Akman T, Oztop I, Unek IT, Koca D, Unal OU, Salman T, Yavuzsen T, Yilmaz AU, Somali I, Demir N, Ellidokuz H, “Long-Term Outcomes and Prognostic Factors of High-Risk Malignant Melanoma Patients after Surgery and Adjuvant High-Dose Interferon Treatment: A Single-Center Experience.”, Chemotherapy, 60/4/228-238, 2015.
- Dirican A, Küçükzeybek BB, Alacacıoğlu A, Küçükzeybek Y, Erten C, Varol U, Somalı I, Demir L, Bayoğlu IV, Yıldız Y, Akyol M, Koyuncu B, Çoban E, Ülger E, Unay FC, Tarhan MO, “Do the derived neutrophil to lymhocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer”, Int J Clin Oncol, 2014.
- Demir L, Ekinci N, Erten Ç, Küçükzeybek Y, Alacacıoğlu A, Somalı I, Can A, Dirican A, Bayoğlu IV, Akyol M, Çakalağaoğlu F, Tarhan MO, “Does Immunohistochemistry Provide Additional Prognostic Data In Gastrointestinal Stromal Tumors?”, Asian Pac J Cancer Prev., 14 (8), 4751-4758, 2013.
- Dirican A, Varol U, Küçükzeybek Y, Alacacıoğlu A, Erten Ç, Somalı I, Can A, Demir L, Bayoğlu IV, Akyol M, Yıldız Y, Koyuncu B, Çoban E, Tarhan MO, “Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?”, Asian Pac J Cancer Prev., 15(12), 4781-4786, 2014.
- Dirican A, Küçükzeybek Y, Aydın A, Demir L, Can A, Bayoğlu IV, Akyol M, Yurtseven S, Somalı I, Erten Ç, Alacacıoğlu A, Çakalağaoğlu F, Tarhan MO, “Induction or Adjuvant Docetaxel / Cisplatin Chemotherapy in Advanced Stage Non-Metastatic Nasopharyngeal Cancer”, Kocatepe Tıp Dergisi, 15(2):92-8, 2014.
- Demir L, Ekinci N, Erten Ç, Somalı I, Can A, Dirican A, Çokmert S, Bayoğlu IV, Akyol M, Küçükzeybek Y, Alacacıoğlu A, Tarhan MO, “The Impact of Cell Proliferation Markers and p53 Mutation Status on Prognosis of Non-Metastatic Colon Cancer”, Journal of Surgical Oncology, 109:665-675, 2014.
- Demir L, Akyol M, Bener S, Payzın KB, Erten Ç, Somalı I, Can A, Dirican A, Bayoğlu IV, Küçükzeybek Y, Alacacıoğlu A, Çallı A, Tarhan MO, “Prognostic Evaluation of Breast Cancer Patients with Evident Bone Marrow Metastasis”, The Breast Journal, Volume 20 Number 3, 279-287, 2014.
- Dirican A, Küçükzeybek Y, Erten Ç, Somalı I, Can A, Bayoğlu V, Akyol M, Çallı AÖ, Alacacıoğlu A, Tarhan MO, “Cardiac rhabdomyosarcoma of the left atrium: a case report”, Contempory Oncology, 18(1); 73-75, 2014.
- Somalı I, Ustaoğlu BY, Tarhan MO, Yiğit SÇ, Demir L, Ellidokuz H, Erten Ç, Alacacıoğlu A, “Clinicopathologic and Demographic Evaluation of Triple- Negative Breast Cancer Patients among a Turkish Patient Population: a Single Center Experience”, Asian Pac J Cancer Prev, 14 (10), 6013-6017, 2013.
- Somalı I, “Kolon Kanseri adjuvan sistemik tedavi yaklaşımları”, Türkiye Klinikleri, 6/3 2013 50-55, 2013.
- Tarhan MO, Gö nel A, Küçükzeybek Y, Erten Ç, Çuhadar S, Yiğit SÇ, Atay A, Somalı I, Dirican A, Demir L, Köseoğlu MH, “Prognostic Signifcance of Circulating Tumor Cells and Serum CA15-3 Levels in Metastatic Breast Cancer, Single Center Experience, Preliminary Results”, Asian Pac J Cancer Prev., 14(3), 1725-1729, 2013.
Erten Ç, Demir L, Somalı I, Alacacıoğlu A, Küçükzeybek Y, Akyol M, Can A, Dirican A, Bayoglu IV, Tarhan MO, “Cisplatin Plus Gemcitabine for Treatment of Breast Cancer Patients with Brain Metastases; a Preferential Option for Triple Negative Patients?”, Asian Pac J Cancer Prev., 14, 3711–3717, 2013.
Demir L, Yiğit S, Ellidokuz H, Erten Ç, Somalı I, Küçükzeybek Y, Alacacıoğlu A, Çokmert S, Can A, Akyol M, Dirican A, Bayoğlu V, Sarı AA, Tarhan MO, “Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs”, Clin Exp Metastasis, 30:1047–1062, 2013.
Demir L, Rezanko TA, Akyol M, Bayoglu IV, Dirican A, Can A, Çokmert S, Küçükzeybek Y, Alacacıoğlu A, Erten Ç, Somalı I, Tarhan MO, “Malignant Hemangiopericytoma: Reports of Two Cases with Different Clinical Course and Review of the Literature”, Türkiye Klinikleri Journal Of Case Reports, 21(1), 18–23, 2013.
Dirican A, Ekinci N, Avcı A, Akyol M, Alacacıoğlu A, Küçükzeybek Y, Somalı I, Erten Ç, Demir L, Can A, Bayoğlu IV, Koyuncu B, Ülger E, Tarhan MO, “The effects of hematological parameters and tumor-infiltrating lymphocytes on prognosis in patients with gastric cancer.”, Cancer Biomarkers, 13, 11–20, 2013.
Dirican A, Küçükzeybek Y, Erten Ç, Somalı I, Demir L, Can A, Payzın KB, Bayoğlu IV, Akyol M, Yıldız Y, Köseoğlu M, Alacacıoğlu A, Tarhan MO, “Prognostic and Predictive Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma: Second Line Sunitinib Treatment Following IFN-alpha.”, Asian Pac J Cancer Prev., 14 (3), 2101–2105, 2013.
Dirican A, Küçükzeybek Y, Tarhan MO, Somalı I, Erten Ç, Demir L, Can A, Bayoğlu IV, Akyol M, Ekinci N, Medeni M, Koyuncu B, Alacacıoğlu A, “One-day DCF regimen in patients with metastatic gastric cancer”, Tumori, 99: 145–148, 2013.
Dirican A, Küçükzeybek Y, Somalı I, Erten Ç, Demir L, Can A, Payzın KB, Bayoğlu IV, Akyol M, Köseoğlu M, Alacacıoğlu A, Tarhan MO, “The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.”, Journal of BUON, 18(2): 413–419, 2013.
Dirican A, Küçükzeybek Y, Somalı I, Erten C, Demir L, Can A, Bayoğlu V, Ermete M, Altınboğa AA, Tarhan MO, “Cutaneous and subcutaneous metastases from bladder carcinoma”, Contemporary Oncology, 16(5): 451–452, 2012.
Tarhan MO, Demir L, Somalı I, Yiğit S, Erten C, Alacacıoğlu A, Ellidokuz H, Seseoğulları O, Küçükzeybek Y, Can A, Dirican A, Bayoğlu V, Akyol M, “The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.”, Clinical & Experimental Metastasis, 2012.
Yiğit S, Demir L, Tarhan MO, Cabuk F, Ellidokuz H, Erten C, Somalı I, Dirican A, Çakalağaoğlu F, “The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma”, Neoplasma, Vol.59, No.5, p.475–485, 2012.
Küçükzeybek Y, Dirican A, Erten Ç, Somalı I, Can A, Demir L, Bayoğlu V, Akyol M, Medeni M, Tarhan MO, “Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.”, Asian Pac J Cancer Prev., 13(6):2771–4, 2012.
Dirican A, Küçükzeybek Y, Somalı I, Erten C, Demir L, Can A, Bayoğlu V, Yiğit SC, Unay FC, Yetimalar MY, Tarhan MO, “Micro metastases into the uterine leiomyoma from invasive ductal breast cancer under adjuvant tamoksifen therapy: case report”, European Journal of Gynaecological Oncology, 2012, 651–655.
Demir L, Erten Ç, Somalı I, Can A, Dirican A, Bayoğlu IV, Küçükzeybek Y, Altınboğa AA, Ermete M, Öztop RM, Tarhan MO, “Metastates Of Renal Cell Carcinoma To The Larynx And Thyroid: Two Case Reports On Metastatis Developing Years After Nephrectomy”, Cuaj-Canadian Urological Association Journal, 6(5); 209–212, 2012.
Demir L, Erten C, Yiğit SC, Can A, Dirican A, Bayoğlu V, Küçükzeybek Y, Somalı I, Tarhan MO, “Intramammary lymph node metastasis in a patient with ovarian carcinoma and a brief review of the literature”, Contemporary Oncology, 16(2): 108–110, 2012.
Demir L, Somalı I, Tarhan O, Erten C, Can A, Dirican A, Ellidokuz H, Bayoglu V, “The Toxicity and Efficacy of Nordic-FLOX regimen as Adjuvant Treatment of stage III Colon Cancer.”, J BUON, 16(4), 2011.
Tarhan O, Alacacioglu A, Somali I, Sipahi H, Zencir M, Erten C, Dirioz M, Oztop I, Niflioglu MO, Yilmaz U, “The association of complementary alternative medicine use with anxiety, depression and quality of life in Turkish cancer patients”, Wspolczesna Onkol, 15 (5)/274–278, 2011.
Alacacioglu A, Kebapcilar L, Sarı İ, Gokgoz Z, Tarhan O, Somalı I, Yuksel A, Bozkaya G, Sop G, “Taxane-based adjuvant chemotherapy reduces endothelin-1 and symmetric dimethylarginine levels in patients with breast cancer.”, J BUON, 15, 462–469, 2010.
Artikel nach Abschluss der medizinischen Facharztausbildung
37. Oztop I, Alacacioglu A, Unek IT, Tarhan MO, Somali I, Cokmert S, Yavuzsen T, Yilmaz AU, “Gemcitabine plus infusional 5-fluorouracil and high dose leucovorin in advanced stage pancreatic cancer”, Journal of BUON, 15/3/462–469, 2010.
38. Tarhan O, Muslu U, Somalı I, Erten C, Alacacioglu A, Varol S, Aslan L, “An Analysis of the Use of Complementary and Alternative Therapies in Patients with Breast Cancer.”, Breast Care, 4, 301–307, 2009.
39. Somalı I, Alacacığlu A, Tarhan O, Meyadan N, Erten Ç, Usalp S, Yılmaz U, “Cisplatin plus Gemcitabine Chemotherapy in Taxane/ Anthracyline-Resistant Metastatic Breast Cancer.”, CHEMOTHERAPY, 55, 155–160, 2009.
40. I. Somali, N. Meydan, MO. Tarhan, I. Oztop, A. Alacacioglu, U. Yilmaz, “Efficacy and toxicity of lower dose UFT without leucovorin in metastatic gastric cancer patients”, J BUON, 14/429–433, 2009.
41. O. Tarhan, A. Alacacioglu, I. Somali, H. Sipahi, M. Zencir, I. Oztop, M. Dirioz, U. Yilmaz, “Complementary-alternative medicine among cancer patients in the western region of Turkey”, J BUON, 14/265–269, 2009.
42. Alacacioglu A, Somali I, Simsek I, Astarcioglu IK, Ozkan M, Camci C, Alkis N, Karaoglu A, Tarhan MO, Unek IT, Yilmaz AU, “Epidemiology and survival of hepatacellular carcinoma in Turkey: outcome of multicenter study”, Japanese Journal of Clinical Oncology, 38/10/683–688, 2008.
43. Kılıçıksız S., Gokce T., Somalı I., Uysal D., Baloğlu A., Yiğit S., “A case with three different synchronous primaries of the female genital system and their treatment.”, J BUON, 12(2); 291–3, 2007.
- 44. U. Yilmaz, I. Oztop, A. Ciloglu, T. Okan, U. Tekin, A. Yaren, I. Somali, A. Alacacioglu, O. Kirimli, "5-fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring", Int J Clin Practice, 61/795-801, 2007.
- 45. Yilmaz U, Oztop I, Alacacioglu A, Yaren A, Tarhan O, Somali I, "Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.", Chemotherapy, 52(5):264-70, 2006.
- 46. Somalı I., Yersal O., Kılıçıksız S., "Infratemporal fossa and maxillary metastases from colorectal cancer: a case report.", J BUON, 11(3):363-5, 2006.
- 47. Kılıçıksız S, Gokce T, Somalı I, Duransoy A., Aydın A., Yigit S., "Combined administration of ethodolac, ascorbic acid and radiotherapy as adjuvant therapies in an extrathoracic desmoid tumor with gross postoperative residual disease; case report and review of the literature.", J BUON, 11(3):355-8, 2006.
- 48. Meydan N, Kundak I, Yavuzsen T, Öztop İ, Barutça S, Yılmaz U, Alakavuklar MN, "Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up.", Jpn J Clin Oncol., 35(5):265-70, 2005.
- 49. Işıl Somalı, İlhan Öztop, Mehmet Füzün, Ali Küpelioğlu, Funda Obuz, Müjde Soytürk, Uğur Yılmaz, "1993-2002 yılları arasında kolorektal kanserli hastalarda uygulanan 5-fluorourasil temelli adjuvan tedavi sonuçları", THOD, 15/29-36, 2005.
- 50. Kundak I, Oztop I, Soyturk M, Ozcan M, Yilmaz A, Meydan N, Bilkay Gorken I, Kupelioglu A, Alakavuklar M, "Paclitaxel-carboplatin induced radiation recall colitis.", Tumori, 90/2/256-8, 2004.
- 51. İlhan Öztop, Arzu Yaren, Işıl Somalı, Oktay Tarhan, Uğur Yılmaz, "Efficiency and tolerability of 5-Fluorouracil based adjuvant chemotherapy in elderly patients with colorectal cancer", Turkish Journal of Cancer, 34/139-145, 2004.
- 53. Ellidokuz EB, Kundak I, Akpınar H, Okan A, Bektaşer C, Füzün M, Tankurt E, Şimşek İ, Gönen Ö, "Kolorektal Polip ve Kanser Lokalizasyonu arasındaki ilişki", Kocatepe tıp dergisi, 1, 47-51, 2003.
- 54. Çehreli R, Somalı I, Alakavuklar M, "Kanser Anoreksi-Kaşeksi Sendromu.", Hematoloji-Onkoloji Güncel Derleme Dergisi, 3(3), 2001.
- 55. Sabri Barutca, Ahsen Karagözlü, Hasan Üstün, Işıl Kundak, Nezih Meydan, İlhan Öztop, Uğur Yılmaz, Mehmet Alakavuklar, "Adjuvan Kemoterapi alan erken evre meme kanseri hastalarında depresyon ve hastaların duygu durumlarını olumsuz etkileyen faktörler", THOD, 10/217-221, 2000.
- 56. Kundak I, Alakavuklar M, "Erken Evre Küçük hücreli dışı akciğer kanserinde kemoterapi uygulamaları", Hematoloji-Onkoloji Güncel Derleme Dergisi, 2(3):234-238, 2000.
- 57. Çımrın A, Sevinç C, Kundak I, Ellidokuz H, İtil O, "Attitudes of medical faculty physicians about taking occupational history.", Medical Education, 33(6):466-7, 1999.
Artikel während des Studiums
- 58. Çımrın A, Sevinç C, Kundak I, Ellidokuz H, "Tıp fakültesi hastanesinde çalışan hekimlerin meslek anamnezi alma alışkanlıkları", Toplum ve Hekim, 13(1):15-19, 1998.
- 59. Mustafa Pehlivan, Kadir Biberoğlu, Oktay Tarhan, Işıl Kundak, Mehmet Ali Özcan, "Nedeni Bilinmeyen Ateş: 62 Olgu Bildirisi", İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi Flora, 3/2/113-119, 1998.
- 60. Okan A, Tankurt İ, Kundak I, Abadoğlu Ö, Soytürk M, Akar S, Okan İ, Ellidokuz H, Aksakoğlu H, "Ventilatöre Bağlı Hastalarda Mortaliteyle İlişkili Prognostik Faktörler", Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, 1, 29-33, 1997.
Autorenschaft von Buchkapiteln
- Akhan G, Doç. Dr. Işıl SOMALI, Duman T, Melek İM, Etiz D, Üstüner Z, "Beyin Tümörleri", İç Hastalıkları, Edt: Çetin Erol, ISBN: 978-975-5676-051, Nobel tıp kitabevi/Ankara, (2008), Syf.4277-4307.
Wissenschaftliche Aktivitäten und Beiträge
In der Akte sind insgesamt 107 Beiträge und Teilnahmen aufgeführt. Die vollständige Liste ist in den Akteninhalten enthalten. Beispielhaft sind unten die erste und die letzte Veranstaltung aufgeführt:
- 10th International Gastrointestinal Cancers Virtual: Posterbeitrag (Dezember 2020).
- 15. Nationaler Kongress für Brusterkrankungen: Freier Vortrag (Oktober 2019).
- Geladener Vortrag: İzmir Uğur Yılmaz Oncology Days (Februar 2021).
- Mitglied der Prüfungskommission: Prüfungskommission für eine Facharztarbeit (Januar 2021).
- Geladener Vortrag: Wandelnde Algorithmen bei hormonpositivem Brustkrebs (Dezember 2020).
- Organisationskomitee/Vortrag: Hedef Kanser 2020, K.K.T.C. (März 2020).
Berufliche Stationen
- Professor: DEÜ, Abteilung für Klinische Onkologie, Onkologie-Institut (Juni 2015 - heute).
- Außerordentlicher Professor: DEÜ, Abteilung für Klinische Onkologie, Onkologie-Institut (Oktober 2011 - Juni 2015).
- Wissenschaftliche Mitarbeiterin/Wissenschaftlicher Mitarbeiter: Medizinische Fakultät der DEÜ (November 1994 - September 2003).
Berufsverbände
- Türkische Gesellschaft für Medizinische Onkologie
- Gesellschaft für Geriatrische Onkologie
- ESMO (Europäische Gesellschaft für Medizinische Onkologie)
- İzmir Onkologiegruppe (İZOG)
- Onkologiegesellschaft Dokuz Eylül

